Trial reportBlood2022
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.
Abstract readClinical TrialLetterMulticenter Study
In one paragraph
Trial report in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants.European journal of cancer (Oxford, England : 1990) · 2023Guideline
- Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.Blood cancer journal · 2022Pooled it
- A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.International immunopharmacology · 2022Pooled it
- 30 years in service, 1996-2026: Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Annals of hematology · 2026Review
- New Technologies and Digital Health Tools in Patients With Solid Tumors and Hematological Malignancies: Cross-Sectional Multicenter Survey Study.JMIR cancer · 2026Article
- Article
- Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.JMIR research protocols · 2025Article
- Seroprevalence of SARS-CoV-2 antibodies in patients with hematological and oncological diseases in early 2024.Blood research · 2025Article
- Effectiveness of early intervention and combination treatment with monoclonal antibodies and antivirals in oncohematological patients with SARS-CoV-2: a retrospective experience.Frontiers in immunology · 2025Article
- Allogeneic 'off-the-shelf' SARS-CoV-2-specific adoptive T-cell therapy for refractory viral infection and end organ disease.Clinical & translational immunology · 2025Article
- [Single-center study of COVID-19 in patients with chronic lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy.Annals of hematology · 2024Article
- Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.Clinical and experimental medicine · 2024Review
- Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.Infection · 2024Article
- Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.EClinicalMedicine · 2024Article
- Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.Microbiology spectrum · 2024Article
- COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant.Cancers · 2024Article
- Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.Influenza and other respiratory viruses · 2024Article
- Efficacy of Combination of Antiviral Therapy With Neutralizing Monoclonal Antibodies for Recurrent Persistent SARS-CoV-2 Pneumonia in Patients With Lymphoma.BioMed research international · 2024Article
- Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies.Viruses · 2023Article
Corrections and comments
- Commented on by
Authors and funding
36 authors.
Livio PaganoDepartment of Hematology, Fondazione Policlinico Universitario Agostino Gemelli-Institute for Cancer Research and Care (IRCCS), Rome, Italy.ORCID 0000-0001-8287-928X
Jon Salmanton-GarcíaDepartment I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Excellence Center for Medical Mycology (ECMM), Cologne, Germany.ORCID 0000-0002-6766-8297
Francesco MarchesiHematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.ORCID 0000-0001-6353-2272
Alberto López-GarcíaFundacion Jimenez Diaz University Hospital, Health Research Institute, Instituto de Investigación Sanitaria-Fundación Jiménez-Díaz (IIS-FJD), Madrid, Spain.ORCID 0000-0002-5354-5261
Sylvain LamureDepartement d'Hematologie Clinique, Centre Hospitalier Universitaire (CHU) de Montpellier, Unité Mixte de Recherche-Centre National de la Recherche Scientifique (UMR-CNRS) 5535, Universite de Montpellier, Montpellier, France.ORCID 0000-0001-5980-305X
Federico ItriSan Luigi Gonzaga Hospital-Orbassano, Orbassano, Italy.ORCID 0000-0002-3532-5281
Maria Gomes-SilvaPortuguese Institute of Oncology, Lisbon, Portugal.ORCID 0000-0002-6993-2450
Giulia DragonettiDepartment of Hematology, Fondazione Policlinico Universitario Agostino Gemelli-Institute for Cancer Research and Care (IRCCS), Rome, Italy.ORCID 0000-0003-1775-6333
Iker Falces-RomeroLa Paz University Hospital, Madrid, Spain.ORCID 0000-0001-5888-7706
Jaap van DoesumDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0003-0214-3219
Uluhan SiliDepartment of Infectious Diseases and Clinical Microbiology, Marmara University, Istanbul, Turkey.ORCID 0000-0002-9939-9298
Jorge LabradorDepartment of Hematology, Hospital Universitario de Burgos, Burgos, Spain.ORCID 0000-0002-3696-0287
Maria CalbachoHospital Universitario 12 de Octubre, Madrid, Spain.ORCID 0000-0001-8106-4863
Yavuz M BilginAdmiraal de Ruijter Hospital, Goes, The Netherlands.ORCID 0000-0003-4854-5424
Barbora WeinbergerováDepartment of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.ORCID 0000-0001-6460-2471
Laura SerranoHospital Universitario de Cabueñes, Gijón, Spain.
José-María Ribera-Santa SusanaHospital Germans Trias i Pujol-Institut Català d'Oncologia Badalona Servicio de Hematología Clínica, Barcelona, Spain.ORCID 0000-0003-1042-6024
Sandra MalakDepartement d'Oncologie Medicale, Hematologie, Institut Curie, Saint Cloud, France.ORCID 0000-0001-8823-5055
José Loureiro-AmigoHospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain.ORCID 0000-0002-6451-8971
Andreas GlenthøjRigshospitalet, Copenhagen, Denmark.ORCID 0000-0003-2082-0738
Raúl Córdoba-MascuñanoFundacion Jimenez Diaz University Hospital, Health Research Institute, Instituto de Investigación Sanitaria-Fundación Jiménez-Díaz (IIS-FJD), Madrid, Spain.ORCID 0000-0002-7654-8836
Raquel Nunes-RodriguesDepartamento de Hematologia, Instituto Português de Oncologia, Lisboa, Portugal.ORCID 0000-0002-8347-4281
Tomás-José González-LópezDepartment of Hematology, Hospital Universitario de Burgos, Burgos, Spain.ORCID 0000-0001-9575-1816
Linda Katharina KarlssonDepartment of Hematology, Center for Hemoglobinopathies, Herlev and Gentofte Hospital, Herlev, Denmark.ORCID 0000-0003-3317-7550
María-Josefa Jiménez-LorenzoHospital Germans Trias i Pujol-Institut Català d'Oncologia Badalona Servicio de Hematología Clínica, Barcelona, Spain.ORCID 0000-0002-5469-5237
José-Ángel Hernández-RivasServicio de Hematología y Hemoterapia, Hospital Universitario Infanta Leonor, Madrid, Spain.ORCID 0000-0003-4550-757X
Ozren JaksicDepartment of Hematology, Dubrava University Hospital, Zagreb, Croatia.
Zdeněk RáčilInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.ORCID 0000-0003-3511-4596
Alessandro BuscaStem Cell Transplant Center, Azienda Ospedaliera-Universitaria (AOU) Citta' della Salute e della Scienza, Turin, Italy.ORCID 0000-0001-5361-5613
Paolo CorradiniUniversity of Milan and Fondazione, IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0002-9186-1353
Martin HoeniglDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA.ORCID 0000-0002-1653-2824
Nikolai KlimkoNorth-Western State Medical University (named after) Iliá Ilich Méchnikov, Saint-Petersburg, Russia.ORCID 0000-0001-6095-7531
Philipp KoehlerDepartment I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Excellence Center for Medical Mycology (ECMM), Cologne, Germany.ORCID 0000-0002-7386-7495
Antonio PagliucaDepartment of Hematological Medicine, King's College Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom.ORCID 0000-0003-2519-0333
Francesco PassamontiDepartment of Medicine, Surgery, University of Insubria and Azienda socio sanitaria territoriale (ASST) Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy.ORCID 0000-0001-8068-5289
Oliver A CornelyDepartment I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Excellence Center for Medical Mycology (ECMM), Cologne, Germany.ORCID 0000-0001-9599-3137
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
COVID-19Hematologic Neoplasms2019-nCoV Vaccine mRNA-1273AdultAgedAged, 80 and overBNT162 VaccineFemaleHumansMaleMiddle AgedSARS-CoV-22019-nCoV Vaccine mRNA-1273BNT162 Vaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.